BackScopus Biopharma Overview

Scopus Biopharma Other Current Liabilities

Latest other current liabilities for SCPS: $11M.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$11.00M

Peer average

Loading

Scopus Biopharma Other Current Liabilities History

Loading

Scopus Biopharma vs. peers: Other Current Liabilities Comparison

Loading

Scopus Biopharma Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Scopus Biopharma (SCPS) FAQ

Scopus Biopharma (SCPS) currently reports a other current liabilities of $11M as of June 2023. In the prior-year period, the figure was $0. Use the charts on this page to explore Scopus Biopharma's other current liabilities history and peer comparisons.

Scopus Biopharma's other current liabilities changed from $0 to $11M (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Scopus Biopharma reported $11M in other current liabilities as of June 2023. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current liabilities of $11M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Scopus Biopharma, and consider following SCPS for alerts when major investors trade the stock.

Scopus Biopharma is classified in the Healthcare sector. On other current liabilities, it currently shows $11M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing SCPS with unrelated industries.